EBV DNA clearance during proton beam therapy study
Part of Cancer, Ear, nose & throat, Infections, Mouth & dental clinical trials.
This trial checks how quickly the Epstein-Barr virus (EBV) DNA in your blood drops to undetectable levels while you receive proton beam therapy for nasopharyngeal cancer. It aims to learn more about the virus's response to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 30 years old.
- You have been diagnosed with a type of nasopharyngeal cancer that is linked to the Epstein-Barr virus (EBV).
- Your cancer is at stage I, II, III, or IVA (not widely spread).
- You are scheduled to start radiation therapy with the goal of curing your cancer.
- You have not had this cancer come back (recur), and you have not had another cancer linked to EBV in the past.
- You have not received radiation therapy before, and you are able to have an MRI without needing sedation or anesthesia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
This trial tests whether the response to initial chemotherapy can guide the dose of radiation given to patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. The goal is to tailor treatment to reduce side effects while still being effective.
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This trial is testing a new way to diagnose nasopharyngeal cancer using a special test that looks at a change in the EBV virus DNA. It is for people who may have symptoms of this cancer or have tested positive for EBV, but have not yet been treated.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.